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Transcriptional Inactivation of STAT3
by PPAR Suppresses IL-6-Responsive
Multiple Myeloma Cells
tion as ligand-dependent, sequence-specific activators
of transcription. Multiple lines of evidence suggest that
PPARs, especially PPAR, play an important role in
modulating cell proliferation, inflammation, and tumor
growth (Debril et al., 2001; Kersten et al., 2000; Koeffler,
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2003). The thiazolidinedione (TZD) class of drugs andSAIC-Frederick
natural ligands including a broad range of polyunsatu-National Cancer Institute-Frederick
rated fatty acids 9- and 13-hydroxyoctadecadienoicFrederick, Maryland 21702
acid (9- and 13-HODE) and the eicosanoids 15-deoxy-2 Cytokine Molecular Mechanisms Section
12,14-prostaglandin J2 (15-d-PGJ2) function as effica-Laboratory of Molecular Immunoregulation
cious PPAR activators. Ligands of PPAR have beenDivision of Basic Sciences
shown to promote differentiation and to inhibit cellNational Cancer Institute-Frederick
growth and induce apoptosis in several types of humanFrederick, Maryland 21702
cancer, suggesting that PPARmay be a tumor suppres-3 Changzheng Hospital
sor gene (Koeffler, 2003). We (Yang et al., 2000, 2002)The Second Military Medical University
and other investigators (Clark et al., 2000) have foundShanghai, 200003
that PPAR also plays an important role in T lymphocyteChina
activation and proliferation. PPAR has also been shown4 Xinhua Hospital
be expressed in normal or mature B lymphocytes andShanghai Second Medical University
B lymphoma cells (Padilla et al., 2002; Schlezinger et al.,Shanghai, 200003
2002). A physiological role for PPAR in B cell function isChina
suggested by an increased proliferative response and
enhanced antigen-specific immune response of mature
B cells from PPAR haploinsufficient mice (SetoguchiSummary
et al., 2001). Padilla et al. (2002) reported that 15-d-
PGJ2, as well as other synthetic PPAR ligands, haveMultiple myeloma (MM) remains largely incurable de-
an antiproliferative and cytotoxic effect on both normalspite conventional and high-dose therapies. There-
and malignant B cells. These findings led us to hypothe-fore, novel biologically based treatment approaches
size that PPAR agonists may inhibit B cell tumors suchare urgently required. Here we demonstrate that ex-
as multiple myeloma.pression of peroxisome proliferator-activated recep-
Multiple myeloma is a malignancy of differentiated Btor  (PPAR) in MM cells and its agonists 15-d-PGJ2
lymphocytes characterized by accumulation of clonaland troglitazone completely abolished IL-6-inducible
plasma cells in the bone marrow and accounts for 10%MM cell proliferation and induced apoptosis through
of all hematologic cancers and remains an incurableaffecting expression of multiple cell cycle or apopto-
hematological malignancy (Reece, 1998; Sjak-Shie etsis genes, whereas PPAR antagonist GW9662 and
al., 2000). The main clinical manifestations of the diseasePPAR agonist WY14643 did not display this inhibitory
include pancytopenia, hyperproteinemia, renal dysfunc-
effect. These PPAR agonists significantly inhibited
tion, bone lesions, and immunodeficiency (Anderson,
DNA binding and transactivation of STAT3 bound to
1999; Hallek et al., 1998; Kastrinakis et al., 2000; Vartera-
the promoter of target genes in chromatin, but did not sian, 1999). Although conventional therapies can extend
affect the expression of IL-6 receptor and phosphory- patient survival to an average of 3–4 years and high-
lation of JAK/STAT3, MAPK, and PI3K/Akt. Interest- dose therapy that is followed by autologous stem-cell
ingly, although inactivation of STAT3 by PPAR ago- transplantation can modestly prolong the survival to 4–5
nists is in a PPAR-dependent manner, the molecular years, MM remains largely incurable. This highlights the
mechanism by which two structurally distinct PPAR urgent need for novel biologically based treatment strat-
agonists suppress IL-6-activated STAT3 shows the di- egies (Hideshima and Anderson, 2002). Interleukin-6 is
vergent interactions between PPAR and STAT3 in- a pleiotropic cytokine with biological activities on a wide
cluding direct or SMRT-mediated association. variety of cells. Normally, IL-6 causes B cell differentia-
tion, but in myeloma it causes proliferation and inhibits
Introduction apoptosis (Klein et al., 1995). IL-6 is particularly involved
in malignant plasma cell expansions. IL-6, derived from
PPAR is a member of the nuclear receptor superfamily either autocrine or paracrine sources, is the key growth
that includes receptors for steroids, thyroids, thyroid and survival factor of multiple myeloma cells (Dankbar
hormone, vitamin D, and retinoic acid. PPAR is ex- et al., 2000; Gado et al., 2000). Furthermore, MM cells
pressed at high levels in adipose tissue and is an impor- usually express functional IL-6 receptors, but some-
tant regulator of adipocyte differentiation, which func- times also produce IL-6 (Westendorf et al., 1996). IL-6
mediates its functions by binding IL-6R and gp130, a
transmembrane protein, which results in the formation*Correspondence: lhwang@ncifcrf.gov (L.H.W.); farrar@ncifcrf.gov
of high-affinity IL-6 binding sites. After receptor stimula-(W.L.F.)
5 These authors contributed equally to this work. tion, three downstream pathways including Janus ki-
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Figure 1. Expression of PPAR and Inhibitory Effects of Its Ligands on Cell Growth and Apoptosis of Human MM Cells
(A) Human MM cells KAS6/1, ANBL-6, and OCI-my5, and human BMSC HS-5 cells were lysed and immunoblotted with anti-PPAR. Adipocytes
were shown as a positive control.
(B–D) Quiescent KAS6/1 (B), ANBL6 (C), or OCI-my5 cells (D) were treated with 2 ng/ml IL-6 and increasing concentrations (abscissa) of 15-
d-PGJ2 (upward-facing arrowhead), Troglitazone (downward-facing arrowhead), or Wy14643 (diamond) for 16 hr at 37C. Cell proliferation
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nase (JAK)/signal transducer and activator of transcrip- tive cells from bone marrow from MM patients. These
patients’ MM cells were cultured for 72 hr with or withouttion (STAT), mitogen-activated protein kinase (MAPK),
PPAR agonists (Figure 1E). Although the percentageand phophatidylinositol-3 kinase (PI3K)/Akt kinase sig-
of inhibition was diverse among the patients, PPARnaling cascades are activated (Hideshima and Ander-
agonists also inhibited the proliferation of freshly iso-son, 2002; Liu et al., 1998). We have demonstrated STAT3
lated myeloma cells.to be a molecular participant in estrogen receptor (ER)
We next determined whether a PPAR antagonistinhibition of the IL-6 signaling pathway in human MM
could restore the inhibition of PPAR agonists on thecells (Wang et al., 2001). While the thiazolinedione group
proliferation of MM cell lines. The cells were incubatedof PPAR agonists has been recently proposed to have
with 15-d-PGJ2 or troglitazone in the presence ofinhibitory effects on Waldenstrom’s macroglobulinemia
GW9662, a pure antagonist of PPAR (Wright et al.,(Mitsiades et al., 2003), the evidence on expression and
2000). The results showed that GW9662 could reversepossible effect of PPAR in MM cell growth or apoptosis
the inhibition of PPAR agonists on IL-6-mediated MMmediated by IL-6 signal pathway is not yet available.
cell proliferation (Figure 1F). Therefore, activation ofIn the present study, we investigated the expression
PPAR by its agonist significantly inhibits IL-6-mediatedof PPAR and its role and molecular targets in cell
proliferation in MM cells. Moreover, such inhibitory ef-growth of multiple myeloma. We provide evidence that
fect is in a PPAR-dependent manner.activated PPAR effectively blocks the IL-6 signal trans-
To evaluate whether these cells treated by PPARduction pathway by inhibiting the DNA binding and tran-
agonists eventually undergo apoptosis, we used a cellscriptional activity of activated STAT3 through divergent
death detection ELISA to assay cytoplasmic histone-protein-protein interaction: 15-d-PGJ2 enhances the di-
associated DNA fragments. Figure 1G showed that treat-rect physiological association, whereas troglitazone in-
ment of PPAR agonists 15-d-PGJ2 and troglitazone,duces redistribution of corepressor SMRT from PPAR
but not PPAR agonist Wy14643, could induce cell apo-to activated STAT3, in turn downregulating IL-6-medi-
ptosis in a dose-dependent manner even in the presenceated MM cell growth and gene expression.
of IL-6. Moreover, GW9662 could overcome this effect,
suggesting PPAR agonists potently inhibited IL-6-
Results mediated antiapoptotic effect on MM cells.
Since various studies have shown that myeloma cells
Expression of PPAR and Effect of Its Ligands on can grow and survive without interleukin-6, we used
IL-6-Inducible Growth and Survival of MM Cells RPMI-8226 to test if PPAR ligands affect MM cell
We first determined expression of PPAR in the MM cell growth without exogenous IL-6. The results (Figure 1H)
lines using Western blot analysis. As shown in Figure showed that PPAR agonists also inhibited this cell pro-
1A, human IL-6-dependent myeloma cell lines, KAS6/1 liferation, which is consistent with the effect of dexa-
and ANBL-6 cells, which are from multiple myeloma methasone and retinoids on these cells, indicating that
patients with aggressive disease and therefore are phe- the above drugs may act to deprive the cells of endoge-
notypically representative of freshly isolated tumor cells, nous or autocrine IL-6 although RPMI-8226 cells are not
predominantly expressed PPAR2 rather than PPAR1, dependent on exogenous IL-6 (Smith et al., 1998).
whereas OCI-My5 cells expressed little or no PPAR
protein. Effects of PPAR Ligands on IL-6 Secretion
Since IL-6 plays a major role in the proliferation of by BMSC and MM
clonal malignant plasma cells in multiple myeloma, we Since IL-6 is produced as a result of interaction between
asked whether the PPAR ligands could block IL-6-medi- myeloma and bone marrow stromal cells (BMSC), we
ated MM cell growth. KAS6/1 (Figure 1B) or ANBL-6 tested if the PPAR agonists affected the levels of solu-
(Figure 1C) cells were cultured in the presence or ab- ble IL-6 in a cocultured MM and stromal cell system.
sence of increasing concentrations of PPAR ligands Human bone marrow stromal cell line HS-5 also ex-
and stimulated by IL-6. IL-6-inducible [3H]-thymidine in- presses PPAR protein (Figure 1A). IL-6 secretion was
corporation was inhibited by PPAR agonists, 15-d- lower to undetectable in the MM cell line KAS6/1 alone.
PGJ2 and troglitazone, in a dose-dependent manner, The supernatants collected from cocultured KAS6/1 and
whereas a PPAR ligand Wy14643 failed to inhibit the HS-5 cells produced a high level of IL-6. Treatment of
above cell growth. In addition, these PPAR ligands did MM-BMSC cultures for 48 hr with PPAR agonists re-
not inhibit cell growth of PPAR-negative OCI-my5 cells vealed a significant decrease in IL-6 level (Figure 2A),
(Figure 1D). indicating that PPAR ligands inhibit the secretion of
To examine the inhibitory effects of PPAR agonists IL-6 by affecting interaction between BMSC and MM
cells.on primary myeloma cells, we have purified CD138-posi-
was assayed by [3H]-thymidine incorporation (n  6). The basal level for unstimulated cells is 4000–6000 cpm.
(E) Primary MM cells derived from patients were treated with or without PPAR ligands. Cell growth was measured by MTS assay as compared
with control cells culture without drugs.
(F) GW9662 restored the PPAR agonists inhibition on IL-6-mediated KAS6/1 cell proliferation assayed by [3H]-thymidine incorporation (n  6).
(G) KAS6/1 cells were treated by PPAR ligands in the presence of IL-6 for 24 hr. The formation of cytoplasmic nucleosomal DNA was
quantitatively measured by a cell death detection ELISA with cell lysates.
(H) RPMI-8226 cells were treated with 1 M 15-d-PGJ2, 10 M Troglitazone, or 50 M Wy14643 without exogenous IL-6. Cell proliferation
was assayed by [3H]-thymidine incorporation (n  6).
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Figure 2. PPAR Ligands Affected Interaction between BMSC and MM Cells and Expression of STAT3-Driven Cell Cycle and Apoptosis Genes.
(A) Effect of PPAR ligands on IL-6 secretion by BMSC/MM cells. IL-6 concentrations were determined in supernatants of cultured KAS6/1
or cocultured HS-5 and KAS6/1 cells.
(B) Freshly isolated mRNA obtained from KAS6/1 cells treated with 1 M 15-d-PGJ2 or 10 M troglitazone and stimulated with IL-6 for 6 hr
at 37C. mRNA was then subjected to RT-PCR analysis using c-myc (upper panel) and GAPDH (lower panel) primers.
(C) The quantitative c-myc mRNA expression levels were normalized against GAPDH level.
(D and E) Freshly mRNA was also hybridized with [33P]-labeled RNA probes corresponding to transcripts for individual human cell cycle- and
apoptosis-regulatory genes and analyzed by RPA.
Effect of PPAR Ligands on Expression of IL-6- 15-d-PGJ2 or troglitazone markedly inhibited mRNA ex-
pression of c-myc (Figures 2B and 2C) and E2F membersMediated Cell Cycle and Apoptosis Regulatory Genes
We further analyzed whether PPAR ligands affect ex- (E2F1, E2F2, and E2F4), but increased expression of
p21, which was downregulated by IL-6 (Figure 2D).pression of IL-6-driven cell cycle- and apoptosis-regula-
tory genes in MM cells. Treatment of KAS6/1 cells with These ligands also significantly decreased expression
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of antiapoptosis genes such as mcl-1, bcl-xl, and bcl-2.
Moreover, 15-d-PGJ2 and troglitazone increased ex-
pression of proapoptotic genes bax and bak although
both genes expressed at a low level in the presence of
IL-6 (Figure 2E), suggesting that regulation of cell cycle
and apoptosis genes by activated PPAR results in the
inhibition of IL-6-mediated MM cell growth.
PPAR Activation Did Not Affect IL-6R
Chain mRNA Expression
Since the initial step in IL-6 signaling requires activation
of its cognate receptor chains, we used RPA assay to
examine whether PPAR-mediated inhibitory effects
were due to reduced expression of IL-6 receptor  (IL-
6R) and  chain (gp130). Treatment of 15-d-PGJ2, trog-
litazone, or Wy14643 failed to show a significant change
in IL-6R and gp130 mRNA expression compared to the
control housekeeping gene GAPDH (Figure 3A). Thus,
blockade of IL-6-mediated cell growth by PPAR ligands
was not due to a loss of IL-6R mRNA expression.
PPAR Ligands Did Not Affect IL-6-induced
Phosphorylation of JAK2/STAT3, MAPK,
and PI3K/Akt
A major signal transduction pathway for IL-6 involves
activation of JAK kinases and the transcription factor
STAT3 (Darnell, 1997; Zhong et al., 1994). Thus, we ex-
amined if the ligand-activated PPAR affects IL-6-
induced tyrosine phosphorylation of JAK2 and STAT3.
Cells were treated with the above ligands and stimulated
with IL-6. Tyrosine phosphorylated JAK2 and STAT3
were observed in exogenous IL-6-stimulated KAS6/1
cells, but not in lysates from unstimulated cells (Figure
3B). PPAR ligands did not inhibit either JAK2 or STAT3
tyrosine phosphorylation in KAS6/1 cells. Immunoblot-
ting of JAK2 and STAT3 (indicated beneath phosphory-
lation blots) verified equivalent loading and no loss of
protein expression. These data suggest that the acti-
vated PPAR does not affect IL-6-induced JAK2 and
STAT3 tyrosine phosphorylation.
Because the MAPK and PI3-K/Akt signal cascades
(Hideshima et al., 2001) are also involved in the prolifera-
tive response of myeloma cells to IL-6, we assayed the
effect of PPAR ligands on the phosphorylation of Erk1/
Erk2, PI3-K, and Akt in KAS6/1 cells. As shown in Figure
3C, IL-6 could dramatically induce the phosphorylation
of Erk1 and Erk2. Treatment with the above ligands also
did not significantly affect IL-6 stimulated phosphoryla-
tion of Erk1/2, PI3-K, and Akt. These results indicate the
inhibitory effect of PPAR ligands on IL-6-mediated cell
Figure 3. PPAR Ligands Do Not Alter mRNA Expression of IL-6
proliferation is not based on inactivation of MAPK and Receptor and IL-6-Induced Tyrosine Phosphorylation of JAK2/
PI3-K/Akt pathways. STAT3, MAPK, and PI3K/Akt
(A) KAS6/1 cells were treated with 1 M 15-d-PGJ2, 10 M troglita-
PPAR Ligands Specifically Blocked IL-6-Induced zone, or 50 M Wy14643. RNA was extracted and hybridized with
[33P]-labeled RNA probes corresponding to transcripts for individualSTAT3 DNA Binding Activity and Transactivation
human IL-6R and gp130 (hCR-2) and analyzed by RPA.IL-6 is known to potently activate STAT3, and to a minor
(B) KAS6/1 cells were treated with 1 M 15-d-PGJ2, 10 M troglita-extent STAT1. To examine the effect of activated PPAR
zone, or 50 M Wy14643 for 2 hr at 37C, and then stimulated with
on the DNA binding activity of STAT3, we performed gel 2 ng/ml IL-6 at 37C for 10 min. Cell lysates were immunoprecipitated
electrophoretic mobility shift assays by the use of a with either anti-JAK2 or anti-STAT3 and immunoblotted with anti-
radiolabeled, double-stranded, STAT3 oligonucleotide phosphotyrosine (upper panel) or reprobed with JAK2 or STAT3
(indicated beneath phosphorylation blots).corresponding to the SIE-element. Nuclear extracts ob-
(C) The above cell lysates were analyzed by immunoblotting withtained from IL-6-stimulated KAS6/1 (Figure 4A) or ANBL-
antibodies specific for phospho-MAPK (p42 and p44), PI3 K, or Akt.6 cells (Figure 4B) displayed considerable SIE DNA bind-
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Figure 4. PPAR Ligands Inhibit IL-6-Induced STAT3 DNA Binding, Transactivation, and STAT3 Occupancy in the c-myc and mcl-1 Promoters
(A and B) KAS6/1 (A) or ANBL-6 (B) cells were treated without or with 15-d-PGJ2, troglitazone, and Wy 14643 at 37C for 2 hr and then
stimulated with medium (-) or 2 ng/ml IL-6 () for 10 min. Nuclear extracts were incubated in the presence of -STAT3 or normal rabbit serum
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ing activity as compared to equivalent protein samples analyzed by RPA. These observations suggest that
PPAR agonists specifically inhibit IL-6-inducible STAT3obtained from non-IL-6 treated cells. These IL-6 induc-
ible DNA complexes could be supershifted with anti- DNA binding and subsequent transcriptional activity in
target cell cycle and apoptosis regulatory genes, whichSTAT3 confirming the identity of STAT3. Following treat-
ment with 15-d-PGJ2 and troglitazone, IL-6 inducible is consistent with the previous observation that activa-
tion of STAT3 is required for IL-6 inducible cell cycleSTAT3 binding activity was decreased, whereas the
PPAR ligand Wy14643 did not affect the binding, sug- progression and survival (Shirogane et al., 1999).
gesting that PPAR ligands 15-d-PGJ2 and troglitazone
inhibit IL-6-induced STAT3 DNA binding activity. Transcriptional Inactivation of STAT3 by PPAR
To quantitatively assess whether PPAR ligands Agonists Is Dependent on the Expression
blocked the transactivation potential of STAT3 in MM and Activation of PPAR
cells, we transfected a STAT3-luciferase reporter gene To explore if inactivation of STAT3 by PPAR ligands is
construct into KAS6/1 cells to quantitatively assess the dependent on expression of PPAR in MM cells, the
effect of the 15-d-PGJ2 and troglitazone on IL-6-stimu- OCI-My5 MM cells were cotransfected with control
lated STAT3 transcriptional activation. As shown in Fig- pSG5 plasmid, a PPAR2 wild-type expression vector
ure 4C, STAT3 luciferase activity of IL-6-stimulated (pSG5-hPPAR2), or PPAR2 mutant, a double point
KAS6/1 cells was substantially reduced in 15-d-PGJ2 mutant in the DNA binding region that can bind ligand
and troglitazone-treated cells. The PPAR antagonist but is unable to bind DNA (Tontonoz et al., 1994), and
GW9662 can significantly overcome the inhibitory effect a STAT3-luciferase reporter gene construct. As shown
of troglitazone. By contrast, IGF-1 alone did not signifi- in Figure 5A, PPAR ligands 15-d-PGJ2 and troglitazone
cantly affect STAT3 luciferase transactivation, which is only inhibited IL-6 inducible STAT3 transactivation in
consistent with the previous reports (Ferlin et al., 2000, PPAR2-expressing, but not in PPAR2 mutant, or
Jourdan et al., 2000). Moreover, although PPAR ago- PPAR2-nonexpressing, transfected OCI-My5 MM
nists decreased the STAT3 transactivation, there was cells. Thus, it is clear that such inhibitory effects on
no significant difference in STAT3 activity between cells STAT3 transactivation are mediated by PPAR, which
stimulated by IGF1 and IL-6 or IL-6 alone, even in the is consistent with the capacity of PPAR ligands to in-
presence of PPAR ligands (Figure 4D). Thus, PPAR hibit the cell growth of PPAR-positive, but not PPAR-
ligands 15-d-PGJ2 and troglitazone selectively inhibit negative, MM cells.
IL-6-induced STAT3 transactivation. In order to verify that the liganded PPAR is capable
of activating gene transcription through a PPRE in hu-
man MM cells, we performed an EMSA assay to examinePPAR Ligands Specifically Blocked IL-6-Induced
whether the PPAR ligands can bind the PPRE se-Occupancy of STAT3 in the c-myc
quence-specific DNA probe. As shown in Figure 5B,and mcl-1 Promoters
KAS6/1 cells showed an endogenous PPRE binding ac-Further confirmation for STAT3 binding to the c-myc
tivity. 15-d-PGJ2 or troglitazone remarkably enhancedor mcl-1 promoter was obtained via CHIP assays on
PPRE DNA binding. Moreover, we transfected a PPRE-chromatin samples from untreated and PPAR ligand-
driven luciferase reporter construct (PPRE-TK) (Formantreated MM cells. Chromatin was prepared using a form-
et al., 1995) into KAS6/1 cells. Addition of the PPARaldehyde crosslinking protocol, and occupancy of the
ligands 15-d-PGJ2 or troglitazone significantly in-promoter was analyzed using specific pairs of primers
creased the PPRE-TK luciferase activity (Figure 5C).spanning the STAT3-responsive region. Antibody di-
Theses data suggest that the inhibitory effects of 15-d-rected against STAT3 precipitated DNA encompassing
PGJ2 and troglitazone on STAT3 activity are directlythe STAT3-responsive element of the c-myc (Figure 4E)
dependent on the expression and activation of PPAR.and mcl-1 (Figure 4F) promoters was found in IL-6 stimu-
lated cells. Significantly decreased binding of STAT3 to
both above promoters was seen in the presence of 15-d- 15-d-PGJ2 Enhances Interaction between
PPAR and IL-6-Activated STAT3PGJ2 and troglitazone. Consequently, PPAR agonists
result in the decreased levels of protein expression of To analyze the molecular basis of inhibition of activated
PPAR on IL-6/STAT3 signal pathway, we utilized ac-Myc and Mcl-1 (Figures 4G and 4H), which is also
in parallel with the above results on mRNA expression coimmunoprecipitation experiment to test for complex
in combination with a [32P]-labeled STAT3 oligonucleotide probe corresponding to the SIE gene promoter. Arrows indicate migrational location
of each nonsupershifted STAT3-DNA complex or free probe.
(C) KAS6/1 cells were transfected with a 3	STAT3 binding element-pGL3 luciferase construct. Cells were then pretreated with 1 M 15-d-
PGJ2, 10 M troglitazone, and/or 50 M GW9662 for 2 hr, and then incubated with or without IL-6 (2 ng/ml) for 16 hr. Luciferase activity of
lysed cells was measured and normalized against protein concentration.
(D) KAS6/1 cells were transfected with a 3	STAT3 binding element-pGL3 luciferase construct. Cells were then pretreated with PPAR ligands
for 2 hr, and then incubated with or without IL-6 (2 ng/ml), IGF-1 (100 ng/ml), or IL-6 and IGF-1 for 16 hr. Luciferase activity of lysed cells was
measured and normalized against protein concentration.
(E and F) CHIP assay, soluble chromatin was prepared from KAS6/1 cells treated with 15-d-PGJ2 or troglitazone and stimulated with IL-6
and immunoprecipitated with anti-phospho-STAT3. The final DNA extractions were amplified using pairs of primers that cover STAT3 binding
sites of the c-myc (E) or mcl-1 (F) promoter.
(G and H) Nuclear extracts from KAS6/1 cells treated with 15-d-PGJ2 or troglitazone and stimulated with IL-6 were analyzed by immunoblotting
with antibodies specific for c-Myc (G) or Mcl-1 (H).
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Figure 5. Transcriptional Inactivation of STAT3 by PPAR Agonists Is Dependent on the Expression and Activation of PPAR
(A) OCI-My5 MM cells were cotransfected with a PPAR2 wild-type (pSG5-hPPAR2), PPAR2 mutant expression vector, or control pSG5
plasmid and a STAT3-luciferase reporter gene construct. Cells were then pretreated with 1 M 15-d-PGJ2, or 10 M troglitazone for 2
hr, and then incubated with or without IL-6 (2 ng/ml) for 16 hr. Luciferase activity of lysed cells was measured and normalized against
protein concentration.
(B) KAS6/1 cells were treated without or with 15-d-PGJ2, troglitazone, Wy14643 at 37C for 2 hr, and then stimulated with medium (-) or 2
ng/ml IL-6 () for 10 min. Nuclear extracts were incubated in combination with a [32P]-labeled PPRE oligonucleotide probe. Arrows indicate
migrational location of each PPAR-DNA complex.
(C) KAS6/1 cells were transfected a PPRE-driven luciferase reporter construct (PPRE-TK). After transfection for 6 hr, cells were treated
with 15-d-PGJ2, troglitazone, or GW9662 for additional 24 hr. Luciferase activity of lysed cells was measured and normalized against
protein concentration.
formation between PPAR and IL-6-induced STAT3. with PPAR in cells induced by IL-6. This phospho-
STAT3 association with PPARwas markedly increasedKAS6/1 cells were treated with 15-d-PGJ2 or troglita-
zone and stimulated by IL-6. Cell extracts were prepared by 15-d-PGJ2, but decreased by troglitazone. These
data indicate that a direct physical protein-protein inter-and immunoprecipitated with a PPAR-specific anti-
body; immunoprecipitates were developed on Western action occurs between nuclear receptor PPAR and ac-
tivated transcription factor STAT3. Moreover, 15-d-blots with a phospho-STAT3 specific antibody. As shown
in Figure 6A, the phospho-STAT3 can be coprecipitated PGJ2, but not troglitazone, enhanced this interaction,
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Figure 6. Negative Regulation of STAT3 by PPAR Activated by Two Structurally Diverse Ligands in MM Cells
(A) Phospho-STAT3 coimmunoprecipitates with PPAR. KAS6/1 cells were treated with or without PPAR ligands for 2 hr and then simulated
with IL-6 as indicated for 10 min before lyses. Western blotting analysis with either anti-phospho-STAT3 (upper panel) or anti-PPAR (lower
panel) was performed on anti-PPAR or anti-IgG immunoprecipitates.
(B) SMRT coimmunoprecipitates with phospho-STAT3 in response to IL-6. Cells were treated and lysed as indicated in (A). Western blotting
analysis with either anti-SMRT (upper panel) or anti-phospho-STAT3 (lower panel) was performed on anti-phospho-STAT3 or anti-IgG immuno-
precipitates.
(C) SMRT coimmunoprecipitates with PPAR. Cells were treated and lysed as indicated in (A). Western blotting analysis with either anti-SMRT
(upper panel) or anti-PPAR (lower panel) was performed on anti-PPAR or anti-IgG immunoprecipitates.
(D) SMRT or empty vectors, a PPAR expression plasmid and a STAT3-luciferase reporter were cotransfected into KAS6/1 cells. Cells were
treated with or without 1 M 15-d-PGJ2, or 10 M troglitazone, or 10 M troglitazone plus 50 M GW9662 and simulated with IL-6. Luciferase
activity of lysed cells was measured and normalized against protein concentration.
(E) KAS6/1 cells were treated and lysed as indicated in (A). Western blotting analysis was performed with anti-PIAS3.
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suggesting that these two classes of PPAR ligands following IL-6 stimulation. PPAR agonists blocked
STAT3 bound to the above promoters in chromatin (Fig-inactivated STAT3 through different mechanisms.
ures 4E and 4F). These results indicated that STAT3
is a molecular target for PPAR ligands blocking IL-6-Redistribution of NCoR/SMRT-Mediated Troglitazone
induced cell growth and IL-6-initiated signaling pathwayTransrepression of STAT3
in MM cells. STAT3 is the main member of STATs family,Since the PPAR, after ligand binding, can shed the
which is activated by IL-6 family of cytokines. STAT3 hascorepressor complex NCoR/SMRT, which, through its
been recognized as an essential molecular for gp130-association with HDAC, represses gene transcription, it
mediated cell growth, survival, and differentiation (Hi-is relevant to determine if the free NCoR/SMRT complex
rano et al., 2000, Bowman et al., 2000). STAT3 alsoreleased by activated PPAR interacts with STAT3
functions as an oncogene (Bromberg et al., 1999) andphosphorylated by IL-6. KAS6/1 cells were treated with
is either required for transformation, enhances transfor-15-d-PGJ2 or troglitazone and stimulated by IL-6. Cell
mation, or blocks apoptosis. Catlett-Falcone et al. (1999)extracts were immunoprecipitated with an antiphospho-
reported that STAT3 is constitutively activated in boneSTAT3-specific antibody; immunoprecipitates were de-
marrow mononuclear cells from patients with multipleveloped on Western blots with an anti-SMRT-specific
myeloma and in the IL-6-dependent human myelomaantibody (Figure 6B). The SMRT can be weakly coprecip-
cell line U266. Moreover, U266 cells are inherently resis-itated with phospho-STAT3, but not by the isotype con-
tant to Fas-mediated apoptosis by upregulating anti-trol IgG, in cells induced by IL-6. This SMRT association
apoptotic protein Bcl-xL. Blocking IL-6 receptor signal-with phospho-STAT3 was significantly enhanced by the
ing from Janus kinases to the STAT3 protein inhibitsPPAR agonist troglitazone, but not 15-d-PGJ2, and
Bcl-xL expression and induces apoptosis, demonstra-attenuated by the PPAR antagonist GW9662. Reimmu-
ting that STAT3 signaling is essential for the survival ofnoblotting of anti-phospho-STAT3 verified equivalent
myeloma tumor cells. Activated STAT3 translocates intoloading and no loss of protein expression. Moreover,
the nucleus to activate target genes. STAT3 is requiredPPAR and SMRT coimmunoprecipitation decreased in
for the regulation of cell cycle regulatory genes such asthe treatment of troglitazone (Figure 6C), indicating that
c-myc and cyclin D1, as well as antiapoptotic genestroglitazone induces redistribution of corepressor SMRT
bcl-2, mcl-1, and bcl-xl (Bromberg et al., 1999; Kiuchifrom PPAR to activated STAT3.
et al., 1999; Zhang and Darnell, 2001; Yoo et al., 2001).In addition, to investigate whether SMRT affects
As evident in Figure 2, we have found that 15-d-PGJ2PPAR inhibition of STAT3 transcriptional activity, we
or troglitazone markedly inhibited mRNA expression ofcotransfected a SMRT or empty vector, and PPAR ex-
c-myc (Figure 2B) and E2F (Figure 2D) as well as antiapo-pression plasmid and a STAT3-luciferase reporter into
ptotic genes mcl-1 and bcl-xl (Figure 2E), whereas theyKAS6/1 cells. As shown in Figure 6D, overexpression of
increased proapoptotic genes bax and bak in IL-6-stim-SMAT potently increased the inhibitory effect of troglita-
ulated MM cells. Thus, transcriptional blockade ofzone-activated PPAR, suggesting that the SMRT, as a
STAT3 and its target downstream genes is a key stepcorepressor, is able to attenuate the transcription of
for activated PPAR inhibition of IL-6-mediated cell sig-STAT3 in its driven target gene promoters. Based on the
naling in human multiple myeloma cell growth.above observation, inhibition of troglitazone-activated
PPAR can suppress the activities of many distinctPPAR on IL-6/STAT3 signaling may be achieved by the
families of transcriptional factors through various mech-troglitazone-induced redistribution of the corepressor
anisms. 15-d-PGJ2, but not thiazolidinediones (rosiglita-SMRT from PPAR into activated STAT3, subsequently
zone and ciglitazone), inhibits cell growth and causestransrepressing STAT3 functions.
downregulation of STAT3 in human oral squamous cell
carcinoma cells through PPAR-independent eventsPIAS3 Is Not Involved in This Cascade of Events
(Nikitakis et al., 2002). How does the PPAR activatedSince the PIAS3 as a coregulator modulates STAT3
by different structurally diverse ligands repress IL-6-transactivation (Chung et al., 1997; Wang et al., 2001),
induced STAT3 transactivation in MM cells? Direct pro-we also evaluated if PIAS3 was involved in PPAR inhibi-
tein-protein interaction between transcription factorstion on STAT3. No significant changes were observed
and ligand-activated nuclear receptors has been shownin IL-6-stimulated KAS6/1 cells in the presence or ab-
to be involved in the regulation of some transcriptionsence of all above PPAR ligands (Figure 6E), indicating
factors (Govind and Thampan, 2001). Zhang et al. (1997)that PIAS3 is probably not involved in the negative regu-
reported that STAT3 acts as a coactivator of nuclearlation of PPAR ligands on IL-6-activated STAT3 sig-
receptor glucocorticoid receptor signaling. Yamamotonaling.
et al. (2000) has shown that active ER directly associates
with STAT3. In the present study on MM cells, we dem-Discussion
onstrated that PPAR indeed interacted with phosphor-
ylated STAT3, which could be enhanced by 15-d-PGJ2Interleukin-6 has an essential role in the malignant pro-
and decreased by troglitazone (Figure 6A). The 15-d-gression of MM by regulating the growth and survival
PGJ2 is a naturally occurring ligand with low affinity ofof myeloma tumor cells (Nilsson et al., 1990; Xu et al.,
PPAR, whereas a class of antidiabetic drugs known as1998). We found PPAR agonists markedly inhibited
thiazolidinediones are high-affinity synthetic ligands ofSTAT3 DNA binding and transactivation (Figure 4) rather
PPAR. Moreover, because the ligand binding pocketthan phosphorylation of JAK2/STAT3, MAPK, and PI3K/
is not static, each PPAR ligand has the potential toAkt, or expression of IL-6 receptor chains (Figure 3).
induce a different conformation of the receptor. There-Moreover, using CHIP assay, we have found that STAT3
was recruited to the promoter of c-myc or mcl-1 gene fore, it is reasonable that these two structurally distinct
Inactivation of STAT3 by PPAR Suppresses MM Cells
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Figure 7. A Schematic Representation of Possible Molecular Events for Negative Regulation of IL-6-Activated STAT3 by PPAR Activated by
Two Structurally Distinct Ligands
15-d-PGJ2 enhances direct physical protein-protein interaction between PPAR and IL-6-activated STAT3; Troglitazone induces redistribution
of corepressor SMRT from PPAR to activated STAT3, in turn transcriptionally inactivating STAT3. SBE, STAT3 binding element; PPRE, PPAR
responsive element.
PPAR agonists suppress IL-6-activated STAT3 through result also is the first to point out that the corepressor
SMRT interacts with STAT3 and subsequently de-diverse molecular mechanisms.
Transcriptional repression is mediated in part by non- creases STAT3 transcriptional activity, which is consis-
tent with the previous observations that coactivatorsDNA binding corepressors. The corepressor NCoR/
SMRT complex, although originally identified on the ba- CBP/p300 and NCoA/SRC1a can function as interacting
partners to regulate STAT3 activity (Xiao et al., 2003)sis of their ability to associate with and confer transcrip-
tional repression through receptors, has been shown to and to transmit the biological effects of extracellular
stimuli and the potential relevance of STAT3 to oncogen-the recruited to many classes of transcription factor and
are in fact components of multiple protein complexes esis (Giraud et al., 2002).
PIAS3, a protein that specifically binds to activatedcontaining histone deacetylase proteins. This associa-
tion with histone deacetylase activity provides an impor- STAT3, inhibits STAT3 transcriptional activity by reduc-
ing DNA binding (Chung et al., 1997). We previouslytant component of the mechanism that allows DNA bind-
ing proteins interacting with NCoR/SMRT to repress showed that estrogen could induce expression of PIAS3
and its inhibition of STAT3 requiring PIAS as a coregula-transcription of specific target genes. PPAR can form
weak interactions with the corepressor NCoR/SMRT tor modulating the crosstalk between ER and STAT3
(Wang et al., 2001). In contrast, we did not observed acomplex (Gurnell et al., 2000). PPAR cannot bind to
DNA while it is associated with the corepressor complex. significant change of PIAS3 in PPAR ligand-treated
MM cells stimulated by IL-6 (Figure 6E), indicating thatAfter ligand binding, PPAR disassociates from the co-
PPAR, unlike ER, inhibits IL-6/STAT3 signaling path-repressor complex, and then binds to DNA through a
way independent of PIAS3.peroxisome proliferator response element. Here, we first
In summary, we have provided sufficient mechanisticclarified that treatment of MM cells with troglitazone
evidence for the inhibitory effects of PPAR ligands ondecreased association of SMRT with PPAR, which re-
MM cell growth. Interestingly, PPAR ligands differ sig-sults in redistribution of corepressor SMRT from PPAR
nificantly in their respective mechanisms of inactivatingto activated STAT3 (Figures 6B and 6C). Furthermore
STAT3. These data provide the proof of principle forthis interaction between SMRT and IL-6-activated
a possible new strategy for the treatment of multipleSTAT3 can be attenuated by a PPAR antagonist
myeloma based on the transcriptional inactivation ofGW9662, confirming the specificity of the exchange of
STAT3 via ligand-activated PPAR.corepressor SMRT induced by the liganded PPAR. Re-
cruitment of SMRT, which is associated with HDAC
Experimental Procedures(Glass and Rosenfeld, 2000; Hu and Lazar, 2000; Li et al.,
2002), by STAT3 leads to transcriptionally inactivating Materials
STAT3 and consequently downregulating IL-6-mediated 15d-prostaglandin J2 (15-d-PGJ2), troglitazone, and WY16463 were
purchased from BIOMOL Research Laboratories Inc. GW9662 wasMM cell growth and gene expression (Figure 7). This
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from Cayman Chemical. Tissue culture materials were from Life Transfection of Luciferase Reporter Plasmids
FuGene-6 (Roche) was used to transfect the STAT3 or PPAR lucif-Technologies (Gaithersburg, MD). Human IL-6 was obtained from
PeproTech (Rock Hill, NJ). STAT3, JAK2, SMRT, phospho-MAPK erase reporter plasmids into KAS6/1 cells or cotransfected STAT3
luciferase reporter with pSG5-PPAR expression plasmids into OCI-(Erk1/2), phospho-PI3K, phospho-Akt, phospho-STAT3, and mono-
clonal antiphosphotyrosine antibodies were purchased from Up- my5 cells for 6 hr. Cells were followed by incubation in serum-free,
phenol red-free medium with or without 2 ng/ml IL-6 and ligandsstate Biotechnology (Lake Placid, NY). The PPAR, PIAS3, c-Myc,
and Mcl-1 antibodies were obtained from Santa Cruz Biotechnology for 16 hr. Luciferase assay were performed according to the manu-
facturer’s instructions (BD PharMingen). To correct for variations(Santa Cruz, CA).
in transfection efficiencies, the luciferase values were normalized
against protein concentration (Yang et al., 2000).
Cell Culture
KAS6/1 and ANBL-6 (kindly provided by Dr. Diane Jelinek) were
Chromatin Immunoprecipitation Assay
maintained in RPMI-1640 medium containing 10% fetal calf serum
The ChIP assays were based on protocal described by Huang et
(FCS), L-glutamine, penicillin-streptomycin, and IL-6 (1 ng/ml). OCI-
al. (2001). Cells were fixed by formaldehyde. Fifty micrograms of
my5 (kindly provided by Dr. H.A. Messner) was cultured in phenol
purified chromatin samples were immunoprecipitated with anti-
red-free Iscove’s Modified Dulbecco’s Medium (GIBCO, NY) (Treon
STAT3 antibody. DNA isolated from immunoprecipitated material
et al., 1998, Hitzler et al., 1991). The cells were deprived of IL-6 and
following reversal of formaldehyde crosslinking was amplified by
serum for 24 hr prior to stimulation. Cells were then treated with
PCR. Promoter-specific primers included c-myc, 5
-AGGGCTTCT
varying concentrations of PPAR ligands and stimulated with 2
CAGAGGCTTG-3
 and 5
-GGATCTCCCTTCCCAGGAC-3
, which
ng/ml of IL-6.
amplify 196 bp (260-480) fragments flanking the STAT3 binding ele-
Multiple myeloma patient cells were obtained from bone marrow
ment; mcl-1, 5
-CCGACCAAGACTTGTTTCCT-3
 and 5
-CACTGC
samples after informed consent for the use of samples for the pur-
AACCTTGACCTCCT-3
, which also amplify 297 bp (356-613) frag-
pose of research. The bone marrow mononuclear cells were sepa-
ment of flanking the STAT3 binding element.
rated using Ficoll-Hypaque density sedimentation, and plasma cells
were purified (95% CD138) by positive selection with anti-CD138
RT-PCRmagnetic-activated cell separation (MACS) microbeads (Miltenyi,
Total RNA preparation, reverse transcription, and PCR reaction wereCA). Primary MM cells were cultured in RPMI1640 supplemented
done as described previously (Wang et al., 2003). The PCR primerswith 20% FCS, L-glutamine, penicillin-streptomycin, and IL-6 (2
specific for c-myc are: forward 5
-CTT CTG CTG GAG GCC ACAng/ml).
GCA AAC CTC CTC-3
, reverse 5
-CCA ACT CCG GGA TCT GGTHuman marrow stromal cell line HS-5 was from ATCC and grown
CAC GCA GGG-3
 (Wolf et al., 2002) which amplify 308 bp fragments.in RPMI 1640 medium supplemented with 10% FCS, L-glutamine,
The housekeeping gene glyceraldehyde-3-phosphate dehydroge-and sodium pyruvate.
nase (GAPDH), as an internal control in parallel PCR reactions, using
the following oligonucleotides: 3
 (5
-TCC ACC ACC CTG TTG CTG
DNA Synthesis and Growth Inhibition Assay TA-3
) and 5
 (5
-ACC ACA GTC CAT GCC ATC AC-3
) will give a
Cell proliferation was examined by measuring DNA synthesis using fragment of 452 bp.
tritiated thymidine (3H-TdR) uptake (Wang et al., 1999). Quiescent
cells (5	 104/well) were plated in hexad in flat-bottom 96-well micro- Coimmunoprecipitation Assays
titer plates in 200 l of growth media, employing 5% FCS in the Cells were lysed in 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM
presence or absence of IL-6 (2 ng/ml). Cells were treated with ligands KCl, and 0.5% Nonidet P-40. Immunoprecipitation was carried out
for 16 hr, and pulsed for the remaining 4 hr of the assay with [3H]- using anti-PPAR or anti-phospho-STAT3 antibody. Western blots
thymidine (0.5 Ci/200 l). [3H]-thymidine incorporation was ana- were performed by anti-phospho-STAT3, anti-SMRT, or anti-PPAR
lyzed by liquid scintillation counting. Cell growth was also measured antibody as previously described (Yang et al., 2000).
by using a CellTiter96 AQueous One Solution Cell Proliferation Assay
(Promega). The assay reagent consists of 3-(4,5-dimethylthiazol-2-
Acknowledgments
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(inner salt, MTS) and an electron coupling reagent (Penazine ethosul-
We are very grateful to Dr. J. Oppenheim for his critical review of
fate; PES).
the manuscript, Drs. R. Evans and M.A. Lazar for providing plasmids,
and Dr. K. Muegge for kind help in the ChIP experiment. This project
has been funded in whole or in part with Federal funds from theEnzyme-Linked Immunosorbent Assay to Detect Apoptosis
NCI/NIH under Contract NO1-CO-12400.The cell death detection ELISA kit (Roche Diagnostics, Germany)
was used to measure cytoplasmic histone-associated DNA-frag-
ment that result from the induction of apoptosis (Wang et al., 2003), Received: August 29, 2003
according to the manufacturer’s instructions. Revised: January 9, 2004
Accepted: January 20, 2004
Published: February 17, 2004
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